Lung Cancer Trial, Recruiting NCT06604689 Sponsor: Fudan University Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06604689
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with non-small cell lung cancer, confirmed by laboratory testing of tissue samples
  • People whose cancer is classified as stage IV (the most advanced stage, meaning the cancer has spread to other parts of the body)
  • People whose cancer has a specific genetic change (mutation) in a gene called EGFR — specifically the L858R mutation or a change in exon 19
  • People aged 18 or older
  • People who have a functional ability score of 70 or higher on the KPS scale, which means they are able to care for themselves and carry out normal activity (confirm with trial site)
  • People who had cancer that had spread to the brain at the time of their diagnosis
  • People who had a full body scan, including a brain MRI, before starting their current cancer treatment
  • People who have received a standard third-generation EGFR-targeted therapy (either on its own or combined with radiation treatment to the brain)
  • People who are willing to attend follow-up appointments after their treatment
  • People who have given their written consent to participate in the trial

Who may not be able to join:

  • People who have more than one primary cancer or cancer that has spread from another source — with the exception of certain early skin cancers or cervical carcinoma in situ that was fully treated more than 5 years ago with no return of the cancer
  • Women who are pregnant or breastfeeding, or those assessed by the study doctor as not being suitable candidates for a brain MRI
  • People whose test results showed no EGFR mutation, or whose EGFR mutation status was never tested
  • People with uncontrolled epilepsy, nervous system conditions, or a history of mental health disorders that the study doctor believes could affect their ability to give informed consent or follow the study requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86-18017312901

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
30 September 2024
Est. completion
1 April 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov